Close Menu

NEW YORK – Fluidigm reported on Tuesday that its preliminary fourth quarter revenues of 2019 are expected to be $32.0 to $32.4 million, which is at the upper end of the company’s guidance range of $29 to $32 million. In its year ago period, the firm posted revenues of $32.3 million.

On average, analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4. During the recently completed quarter, it had mass cytometry annualized consumables pull-through of about $72,000. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.

Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.